These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 10850310)

  • 41. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Recent progress in rituximab therapy and its resistance--how do we overcome?].
    Hatake K; Yokoyama M; Terui Y
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1177-82. PubMed ID: 17687198
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intrapleural instillation of rituximab for the treatment of malignant pleural effusions in NHL.
    Schmidt HH; Renner H; Linkesch W
    Haematologica; 2004 Nov; 89(11):ECR39. PubMed ID: 15533844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.
    Davis TA; White CA; Grillo-López AJ; Velásquez WS; Link B; Maloney DG; Dillman RO; Williams ME; Mohrbacher A; Weaver R; Dowden S; Levy R
    J Clin Oncol; 1999 Jun; 17(6):1851-7. PubMed ID: 10561225
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
    Bosly A; Keating MJ; Stasi R; Bradstock K
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rituximab: an innovative therapy for non-Hodgkin's lymphoma.
    Wood AM
    Am J Health Syst Pharm; 2001 Feb; 58(3):215-29; quiz 230-2. PubMed ID: 11217177
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New developments in immunotherapy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Ruan J; Coleman M
    Curr Oncol Rep; 2005 Sep; 7(5):364-71. PubMed ID: 16091197
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
    Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overview of antibody therapy in B-cell non-Hodgkin's lymphoma.
    Wannesson L; Ghielmini M
    Clin Lymphoma; 2003 Aug; 4 Suppl 1():S5-12. PubMed ID: 14556670
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma.
    Scott SD
    Cancer Pract; 1998; 6(3):195-7. PubMed ID: 9652253
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ofatumumab in the treatment of non-Hodgkin's lymphomas.
    Karlin L; Coiffier B
    Expert Opin Biol Ther; 2015 Jul; 15(7):1085-91. PubMed ID: 26043777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lymphoid aggregates in bone marrow mimic residual lymphoma after rituximab therapy for non-Hodgkin lymphoma.
    Douglas VK; Gordon LI; Goolsby CL; White CA; Peterson LC
    Am J Clin Pathol; 1999 Dec; 112(6):844-53. PubMed ID: 10587708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radioimmunotherapy for non-Hodgkin's lymphoma.
    Liebenguth P; Vogt Temple S
    Semin Oncol Nurs; 2006 Nov; 22(4):257-66. PubMed ID: 17095402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical applications of anti-CD20 antibodies.
    Gopal AK; Press OW
    J Lab Clin Med; 1999 Nov; 134(5):445-50. PubMed ID: 10560936
    [No Abstract]   [Full Text] [Related]  

  • 59. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
    Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
    Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis.
    Hainsworth JD
    Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S12-6. PubMed ID: 15180892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.